J&J’s Stelara Beats Enbrel In Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
New survey shows doctors are warming to another rival, Humira.
You may also be interested in...
Amgen Taps GSK's Stiefel Unit To Promote Enbrel To Dermatologists
Deal will aid Amgen's promotional efforts around Enbrel in psoriasis as the entrenched biologic faces down Humira, Stelara in the market.
Amgen Taps GSK's Stiefel Unit To Promote Enbrel To Dermatologists
Deal will aid Amgen's promotional efforts around Enbrel in psoriasis as the entrenched biologic faces down Humira, Stelara in the market.
Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class